Enterome appoint Alessandra Cervino
Enterome bioscience, a developer of innovative disease management solutions based on a deep understanding of the gut microbiome, has announced that Alessandra Cervino has joined the company as head of discovery.
Cervino brings over 15 years of experience in the discovery and development of genetic and genomic biomarkers, and has for the past year been consulting to Enterome in relation to its core technologies. As head of discovery at Enterome, she will lead a team of bioinformaticians and biostatisticians to deepen the company’s understanding of the gut microbiome through a metagenomics approach with the goal of developing a new generation of disease biomarkers, companion diagnostics products and new therapy solutions.
Before joining Enterome, Cervino was vice president of R&D and Biostatistics at TCLand expression, a personalised medicine company developing companion diagnostics and biomarkers for immune disorders and transplantation. She was previously head of Statistical Sciences and assistant professor at Scripps Florida, where she conducted the first genome-wide study of lupus and developed an innovative workflow that combines genotypic and transcriptomic data to identify novel genes. She was the first group leader in statistical genetics at Rosetta Inpharmatics/Merck in the USA, where she played a pioneering role in translating genetic research programs into new drug targets and pharmacogenomic programs.
Pierre Belichard, CEO at Enterome, said: ‘We are pleased that Alessandra has joined to lead our discovery efforts. Our unique Metagenotyping process is allowing us to create new industry standards in the quantitative and functional analysis of the gut microbiome as it relates to health and disease. Under her leadership we are confident that our discovery team will be able to drive the development of new disease management solutions based on this key understanding.’